logo
REIT ScreenerREIT EarningsREIT SectorsMarketplaceLearn
Logo

Keros Therapeutics, Inc.

KROS

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopeā€¦ read more

Healthcare

Biotechnology

3 years

USD

Become a Premium user to unlock the Score details

Price

per share adjusted in USD

$13.49

Price

-0.15%

-$0.02

$13.51

Previous Close

$13.46

Open

81.4%

52w Discount
Market Cap

$547.902m

Small

Price/Earnings

-56.2x

-

3y Avg

-

5y Avg

Dividends

Ex-Dividend: -

0.00%

Yield

$0.00

Dividend

0.00%

Forward Dividend Growth

-

-

3y CAGR

-

5y CAGR
Payout

0.00%

-

Payout 3y

-

Payout 5y
Yield
Benchmark

Dividends

No items found.

Financials Overview

Limited financial history

Premium

-

EBITDA Margin

-

Net Profit Margin

-

Free Cash Flow Margin
Revenue

$214.713m

-

1y CAGR

-

3y CAGR

-

5y CAGR
Earnings

$4.212m

-

1y CAGR

-

3y CAGR

-

5y CAGR
EPS

-$0.24

-

1y CAGR

-

3y CAGR

-

5y CAGR
Book Value

$728.871m

$784.561m

Assets

$55.690m

Liabilities

$18.413m

Debt
Debt to Assets

2.4%

-6.1x

Debt to EBITDA
Free Cash Flow

$43.312m

-

1y CAGR

-

3y CAGR

-

5y CAGR

Financial Reports

Limited financial history

Premium

No items found.
Press Releases
Statements and updates from the company
ā†‘ TopSummaryPriceDividendsFinancialsPress Releases
logo
About usFAQ
All the information presented is collected from official and public documents such as: Quarterly and Annual Reports, 10-K (US), Information Form (Canada), Presentations and the Investor Relations (IR) section of the company's website.
The data displayed by alreits.com is solely for informational purposes, we do not recommend the buying, holding or selling of any of the stocks on the website. If you have no experience in the stock market, please talk to your personal licensed investment advisor before making any decisions.